click below
click below
Normal Size Small Size show me how
WEEK 2:
Pharmaceutical factors affecting drug bioavailability + dose calculations:
| Question | Answer |
|---|---|
| types of oral preparations to treat GIT conditions (3) | suspension, tablet, and capsule |
| examples of fast oral formulations | aqueous, solutions, syrups, and elixirs |
| examples of middle pace oral formulations | suspensions, chewable tablets, granules, capsules, and conventional tablet |
| examples of slow oral formulations | compressed tablets, enteric coated tablets, and controlled release tablets |
| why should certain drugs not be prescribed as same formulation | their bioavailability may change |
| modified or sustained release preparations | formulated to resist dissolution and may be used to reduce absorption rate and prolong action, and deliver drug to specific region of GIT |
| morphine | opioid analgesic |
| nifedipine | dihydropyridine (DHHP) calcium channel blockers (CCBs) used to treat hypertension and angina |
| nifedipine half life | 2-5 hours |
| immediate release preparations of nifedipine are associated with | increased cardiac events (rapid onset of action and short duration of action) where ideally a long acting preparation is prescribed based on patient needs (prolonged duration of action) |
| omeprazole | acid labile (break down when in acidic conditions of stomach) |
| therapeutic uses of omeprazole (4) | indigestion, heartburn and acid reflux, stomach ulcers, and Zollinger-Ellison syndrome |
| enteric coat meaning | acid resistance coat capsule |
| role of omeprazole | act systemically to inhibit proton pumps in parietal cells and is activated at acidic pH |
| when should IV omeprazole be given | in an emergency eg bleeding ulcer or if patient cannot swallow |
| glyceryl trinitrate and fentanyl are applied as what form | patches to provide sustained release |
| skin patches available (2) | glyceryl trinitrate and fentanyl, and fentanyl only patches |
| fentanyl patches | replace oral morphine and use equivalent doses eg patient taking 60mg morphine daily switch to 25mcg/hr fentanyl pathces |
| patients who cannot swallow include (3) | stroke patients (who may need drugs via NG tube or IV line), severe infection (given IV antibiotics), and palliative care patients (morphogenic no longer swallowed and swapped to fentanyl patches or diamorphine via syringe driver) |
| different types of insulin preparations (3) | short acting, intermediate action and long acting |
| depot injections (deep IM) are used when | to aid compliance with injections weekly/monthly |
| unit | measure of power or action of drug (measure of biological activity) |
| factors affecting bioavailability | dosage form and brand (different brands have different bioavailabilities) |
| half life of morphine | 2-3 hours |
| oramorph | oral suspension of morphine for immediate pain relief |
| morphogesic SR | sustained release tablet of morphine and provides 12 hourly pain relief which is prescribed 12 hourly (BD or BID) |
| when is morphogesic SR prescribed | 12 hourly BD/BID |
| dosing regiment for nifedipine (immediate release capsule) | 5-20mg 3 times a day |
| dosing regiment for nifedipine (modified release tablet) | 20mg twice daily |
| dosing regiment for nifedipine (slow release tablet) | 30mg once a day |
| when is omeprazole given | as enteric coated (EC- acid resistant)/ gastro-resistant capsules/tablets usually (as they are acid labile) but other dosage forms are available to address patients needs |
| when does omeprazole degrade | capsule degrades at pH 5-6 |
| glyceryl trinitrate and fentanyl are formulated with what | ethanol |
| glyceryl trinitrate and fentanyl are formulated with ethanol for what reason | to enhance skin penetration |
| describe short acting insulin preparations | soluble rapid onset and short duration |
| describe intermediate action insulin preparations | suspension with protamine useful for twice daily regimens |
| describe long acting insulin preparations | large crystals with high zinc content and slow onset and long duration |
| describe absorption of depot injections (deep IM) | absorption by use of thick oils that slow down rate of diffusion from injection site and avoids first pass metabolism |
| norethisterone enanthate in oil | contraception lasting 8 weeks |
| fluphenazine decanoate in oil | treat schizophrenia with prolonged action and side effects |
| stroke patients who cannot swallow may need what type of treatment | review of medication and may need to administer drugs via NG-tube or IV line |
| patients with severe infection may need what type of treatment | IV antibiotics |
| patients in palliative care may need what type of treatment | fentanyl patches (since morphogesic is no longer swallowed) or diamorphine via syringe driver |